References
- Campochiaro PA, Heier JS, Feiner L, Gray S, Saroj N, Rundle AC, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end-point results of a phase III study. Ophthalmology 2010;117:1102–1112.
- Farinha C, Marques JP, Almeida E, Baltar A, Santos AR, Melo P,et al. Treatment of retinal vein occlusion with ranibizumab in clinical practice: longer-term results and predictive factors of functional outcome. Ophthalmic Res 2015;55(1):10–18.
- Lu X, Sun X. Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des DevelTher 2015;9:2311–2320.
- Zhang M, Zhang J, Yan M, Luo D, Zhu W, Kaiser PK, et al. A phase 1 study of KH902, a vascular endothelial growth factor receptor decoy, for exudative age-related macular degeneration. Ophthalmology 2011; 118(4):672–678.
- Su L, Ren X, Wei H, Zhao L, Zhang X, Liu J, et al. Intravitreal conbercept (KH902) for surgical treatment of severe proliferative diabetic retinopathy. Retina 2016;36(5):938–943.
- Qu J, Cheng Y, Li X, Yu L, Key X; AURORA Study Group. Efficacy of intravitreal injection of conbercept in polypoidal choroidal vasculopathy: subgroup analysis of the aurora study. Retina 2016;36(5):926–929
- Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16:4604–4013
- Noma H, Minamoto A, Funatsu H, Tsukamoto H, Nakano K, Yamashita H, et al. Intravitreal levels of vascular endothelial growth factor and interleukin-6 are correlated with macular edema in branch retinal vein occlusion. Graefes Arch Clin Exp Ophthalmol 2006;244:309–315.
- Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG,et al. Ranibizumab for macular edema due to retinal vein occlusions: Long-term follow-up in the HORIZON trial. Ophthalmology 2012;119:802–809.
- Li X, Xu G, Wang Y, Xu X, Liu X, Tang S, et al. Safety and efficacy of conbercept in neovascular age-related macular degeneration: results from a 12-month randomized phase 2 study: AURORA study. Ophthalmology 2014 Sep;121(9):1740–1747.
- Narayanan R, Panchal B, Das T, Chhablani J, Jalali S, Ali MH, et al. A randomized, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular oedema due to branch retinal vein occlusion: MARVEL Report No. 1. Br J Ophthalmol 2015 Jul; 99(7):954–959.
- Miwa Y, Muraoka Y, Osaka R, Ooto S, Murakami T, Suzuma K, et al. Ranibizumab for macular edema after branch retinal vein occlusion: one initial injection versus three monthly injections. Retina 2016 Jul 28.
- Ahn SJ, Ahn J, Woo SJ, Park KH. Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion. Biomed Res Int 2013;(3):491–512.